Index Event, Clinical Outcomes and Response to Vericiguat in the Victoria Trial
Carolyn S.P. Lam(University of Glasgow), Paul W. Armstrong(Canadian VIGOUR Centre), Burkert Pieske(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Adrian F. Hernandez(Duke University), Jens Refsgaard, Kevin Anstrom(PragmatIC (United Kingdom)), Karen Sliwa(University of Cape Town), Anna Giczewska, Frank Edelmann, Mahesh J. Patel, E A Bocchi(Universidade de São Paulo), Lothar Roessig(Bayer (Germany)), Christopher O’Connor(Duke University), Justin A. Ezekowitz(University of Alberta)
Unknown
January 1, 2020
Cited by 0
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
|European Journal of Heart Failure|2012|2.6k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k